A series of cardiometabolic-related news items has been observed by Medtronic, Roche, Viking Therapeutics, Zealand Pharma, Sanofi, Merck, and Esperion. Below, FENIX provides highlights and insights for the respective news items.
Medtronic announced FDA approval of the supplemental PMA for Medtronic’s Simplera Sync CGM sensor for use with the MiniMed 780G system. Recall, the standalone Simplera CGM was approved by FDA in August 2024 (previous FENIX insight). According to the press release, a limited US launch of the Simplera Sync sensor will begin in Fall 2025. Below, FENIX provides brief insight into the approval.
A series of cardiometabolic-related news items has been observed from Metsera, Beta Bionics, Viking Therapeutics, Vivani Medical, and Dexcom. Below, FENIX provides highlights and insights for the respective news items including the first-ever earnings calls from Metsera and Beta Bionics.
Three cardiometabolic-related news items have been observed from Insulet, MetaVia, and Ampersand Biomedicines. Below, FENIX provides highlights and insights for the respective news items.
On the first day of ATTD 2025, four cardiometabolic-related news items have been observed from Dexcom, Tandem Diabetes Care, Sequel Med Tech, and Welldoc. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: all 15 drug manufacturers agreed to participate in the second round CMS pricing negotiations (view press release) and Ypsomed and CamDiab launched mylife Loop on iOS systems (view press release).
A series of cardiometabolic-related news items has been observed from Bayer, Dexcom, Zealand Pharma, vTv Therapeutics, and Entera Bio/OPKO Health. Below, FENIX provides highlights and insight for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, BI, Mineralys Therapeutics, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Senseonics, Esperion, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Tandem Diabetes Care, Altimmune, Zevra Therapeutics, TIXiMED, MannKind, Silence Therapeutics, and Viatris. Below, FENIX provides highlights and insights for the respective news items.